Glenmark Life Sciences Limited (GLS.BO)
INR 1085.8
(0.0%)
INR 1085.8
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.84 Billion INR | -7.49% |
| 2022 | -2.64 Billion INR | 48.07% |
| 2021 | -5.09 Billion INR | -162.31% |
| 2020 | 8.17 Billion INR | 8291.55% |
| 2019 | -99.77 Million INR | -389.07% |
| 2018 | -20.4 Million INR | -241.37% |
| 2017 | 14.43 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.01 Billion INR | 206.1% |
| 2024 Q2 | -4.43 Billion INR | -242.62% |
| 2023 Q2 | -4.24 Billion INR | -237.26% |
| 2023 Q1 | 3.09 Billion INR | 216.99% |
| 2023 FY | -2.84 Billion INR | -7.49% |
| 2023 Q4 | -2.84 Billion INR | -164.16% |
| 2023 Q3 | 4.43 Billion INR | 204.33% |
| 2022 Q1 | 5.12 Billion INR | 200.57% |
| 2022 Q3 | 3.64 Billion INR | 202.09% |
| 2022 Q2 | -3.57 Billion INR | -169.72% |
| 2022 FY | -2.64 Billion INR | 48.07% |
| 2022 Q4 | -2.64 Billion INR | -172.54% |
| 2021 Q2 | -4.22 Billion INR | -456.9% |
| 2021 FY | -5.09 Billion INR | -162.31% |
| 2021 Q1 | 1.18 Billion INR | -85.51% |
| 2021 Q4 | -5.09 Billion INR | -219.49% |
| 2021 Q3 | 4.26 Billion INR | 200.86% |
| 2020 Q1 | 99.98 Million INR | 0.0% |
| 2020 Q4 | 8.17 Billion INR | 7484.76% |
| 2020 Q3 | -110.67 Million INR | 0.0% |
| 2020 FY | 8.17 Billion INR | 8291.55% |
| 2019 FY | -99.77 Million INR | -389.07% |
| 2018 FY | -20.4 Million INR | -241.37% |
| 2017 FY | 14.43 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 173.532% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 176.968% |
| Granules India Limited | 9.28 Billion INR | 130.61% |
| Indoco Remedies Limited | 6.47 Billion INR | 143.893% |
| Achyut Healthcare Limited | -3.74 Million INR | -75785.211% |
| Ajanta Pharma Limited | -954.9 Million INR | -197.692% |
| Alkem Laboratories Limited | -1.6 Billion INR | -76.629% |
| Alpa Laboratories Limited | 35.36 Million INR | 8138.515% |
| Brooks Laboratories Limited | 49.48 Million INR | 5844.488% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 43.288% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 186.168% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -145.533% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 122.014% |
| Eris Lifesciences Limited | 13.8 Billion INR | 120.589% |
| FDC Limited | -57.75 Million INR | -4822.185% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 33.664% |
| Gufic Biosciences Limited | 3.19 Billion INR | 188.991% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 31.553% |
| Ipca Laboratories Limited | 11.41 Billion INR | 124.902% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -104.518% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 247.066% |
| Lasa Supergenerics Limited | 205.79 Million INR | 1481.28% |
| Laurus Labs Limited | 24.38 Billion INR | 111.658% |
| Lupin Limited | 17.19 Billion INR | 116.534% |
| Mankind Pharma Limited | -9.9 Billion INR | 71.309% |
| Medicamen Biotech Limited | 160.31 Million INR | 1873.161% |
| Medico Remedies Limited | 78.67 Million INR | 3713.076% |
| Megasoft Limited | 1.28 Billion INR | 321.124% |
| NATCO Pharma Limited | -5.81 Billion INR | 51.132% |
| Piramal Pharma Limited | 42.27 Billion INR | 106.724% |
| RPG Life Sciences Limited | -364.7 Million INR | -679.452% |
| Sigachi Industries Limited | 859.94 Million INR | 430.561% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 96.077% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 2060.78% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 6251.479% |
| Unichem Laboratories Limited | 931.91 Million INR | 405.034% |
| Wanbury Limited | 1.1 Billion INR | 357.051% |
| Windlas Biotech Limited | -273.04 Million INR | -941.115% |
| ZIM Laboratories Limited | 983.6 Million INR | 389.005% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 172.665% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -201.833% |
| Divi's Laboratories Limited | -39.77 Billion INR | 92.852% |
| Hester Biosciences Limited | 2.29 Billion INR | 224.094% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -21.067% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -1042.585% |
| Bal Pharma Limited | 1.26 Billion INR | 324.972% |
| Strides Pharma Science Limited | 23.25 Billion INR | 112.223% |
| Venus Remedies Limited | -267.7 Million INR | -961.883% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 208.835% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 146.167% |
| Shilpa Medicare Limited | 9.06 Billion INR | 131.343% |
| Aarti Drugs Limited | 5.54 Billion INR | 151.234% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -158.119% |
| Suven Life Sciences Limited | -1.63 Billion INR | -74.108% |
| Ind-Swift Limited | 9.5 Billion INR | 129.896% |
| Valiant Laboratories Limited | -295.03 Million INR | -863.509% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 200.761% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 128.344% |
| Themis Medicare Limited | 764.96 Million INR | 471.608% |
| Hikal Limited | 7.96 Billion INR | 135.68% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 108.931% |
| Sequent Scientific Limited | 4.17 Billion INR | 168.029% |
| Novartis India Limited | -5.89 Billion INR | 51.747% |
| Wockhardt Limited | 18.27 Billion INR | 115.559% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 110.5% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -15310.712% |
| Neuland Laboratories Limited | -214.05 Million INR | -1227.986% |
| Morepen Laboratories Limited | -231.17 Million INR | -1129.663% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 2468.114% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 391.313% |